| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 61 | 2020 | 361 | 7.130 |
Why?
|
| Brain Neoplasms | 69 | 2021 | 647 | 6.470 |
Why?
|
| Neoplasm Recurrence, Local | 21 | 2020 | 384 | 2.070 |
Why?
|
| Glioma | 15 | 2021 | 136 | 1.730 |
Why?
|
| Meningioma | 10 | 2020 | 58 | 1.340 |
Why?
|
| Trigeminal Neuralgia | 9 | 2019 | 33 | 1.200 |
Why?
|
| Meningeal Neoplasms | 8 | 2017 | 50 | 1.150 |
Why?
|
| Middle Aged | 86 | 2020 | 12125 | 1.130 |
Why?
|
| Retrospective Studies | 49 | 2020 | 3701 | 1.100 |
Why?
|
| Laser Therapy | 6 | 2020 | 56 | 1.090 |
Why?
|
| Treatment Outcome | 45 | 2020 | 3438 | 1.090 |
Why?
|
| Glioblastoma | 12 | 2020 | 157 | 1.030 |
Why?
|
| Salvage Therapy | 16 | 2020 | 134 | 0.990 |
Why?
|
| Adult | 67 | 2020 | 9560 | 0.980 |
Why?
|
| Aged | 69 | 2020 | 10538 | 0.970 |
Why?
|
| Female | 91 | 2020 | 20261 | 0.920 |
Why?
|
| Humans | 112 | 2020 | 32798 | 0.910 |
Why?
|
| Male | 84 | 2020 | 19641 | 0.890 |
Why?
|
| Parkinson Disease | 9 | 2020 | 89 | 0.820 |
Why?
|
| Intracranial Arteriovenous Malformations | 3 | 2012 | 20 | 0.760 |
Why?
|
| Deep Brain Stimulation | 8 | 2020 | 49 | 0.760 |
Why?
|
| Magnetic Resonance Imaging | 18 | 2018 | 1307 | 0.750 |
Why?
|
| Antineoplastic Agents, Alkylating | 5 | 2018 | 40 | 0.750 |
Why?
|
| Negative-Pressure Wound Therapy | 4 | 2016 | 35 | 0.690 |
Why?
|
| Antineoplastic Agents | 9 | 2020 | 599 | 0.690 |
Why?
|
| Follow-Up Studies | 26 | 2020 | 2284 | 0.690 |
Why?
|
| Drug Delivery Systems | 5 | 2021 | 105 | 0.680 |
Why?
|
| Cerebellar Neoplasms | 2 | 2019 | 11 | 0.680 |
Why?
|
| Postoperative Complications | 6 | 2019 | 828 | 0.680 |
Why?
|
| Brain | 6 | 2015 | 946 | 0.650 |
Why?
|
| Aged, 80 and over | 33 | 2020 | 4032 | 0.650 |
Why?
|
| Cranial Irradiation | 9 | 2020 | 93 | 0.640 |
Why?
|
| Hemangioblastoma | 1 | 2019 | 4 | 0.600 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2019 | 5 | 0.600 |
Why?
|
| Neurosurgical Procedures | 4 | 2015 | 100 | 0.530 |
Why?
|
| Combined Modality Therapy | 11 | 2018 | 563 | 0.520 |
Why?
|
| Carmustine | 3 | 2015 | 8 | 0.520 |
Why?
|
| Dura Mater | 2 | 2012 | 14 | 0.460 |
Why?
|
| Stereotaxic Techniques | 5 | 2020 | 23 | 0.450 |
Why?
|
| Convection | 3 | 2021 | 8 | 0.440 |
Why?
|
| Treatment Failure | 12 | 2020 | 156 | 0.430 |
Why?
|
| Young Adult | 17 | 2020 | 2730 | 0.420 |
Why?
|
| Corpus Striatum | 3 | 2020 | 62 | 0.410 |
Why?
|
| Radiotherapy | 6 | 2018 | 82 | 0.400 |
Why?
|
| Disease-Free Survival | 10 | 2020 | 326 | 0.380 |
Why?
|
| Craniocerebral Trauma | 1 | 2012 | 58 | 0.370 |
Why?
|
| Subthalamic Nucleus | 5 | 2020 | 13 | 0.360 |
Why?
|
| Facial Pain | 5 | 2014 | 21 | 0.350 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2017 | 80 | 0.340 |
Why?
|
| Genetic Vectors | 2 | 2010 | 120 | 0.340 |
Why?
|
| Survival Analysis | 14 | 2020 | 486 | 0.340 |
Why?
|
| Melanoma | 6 | 2019 | 165 | 0.330 |
Why?
|
| Multiple Sclerosis | 3 | 2019 | 60 | 0.320 |
Why?
|
| Survival Rate | 11 | 2020 | 894 | 0.320 |
Why?
|
| Serotonin | 2 | 2020 | 37 | 0.300 |
Why?
|
| Anticonvulsants | 1 | 2009 | 65 | 0.300 |
Why?
|
| Radiation Injuries | 5 | 2018 | 78 | 0.300 |
Why?
|
| Lung Neoplasms | 5 | 2017 | 428 | 0.290 |
Why?
|
| Radiotherapy Dosage | 9 | 2017 | 99 | 0.280 |
Why?
|
| Nomograms | 4 | 2017 | 35 | 0.270 |
Why?
|
| Adolescent | 11 | 2020 | 3638 | 0.270 |
Why?
|
| Dopamine | 3 | 2020 | 234 | 0.270 |
Why?
|
| Neoplasms | 4 | 2020 | 761 | 0.270 |
Why?
|
| Decision Making | 2 | 2020 | 202 | 0.260 |
Why?
|
| Prognosis | 10 | 2020 | 1544 | 0.260 |
Why?
|
| Hypothalamo-Hypophyseal System | 4 | 2008 | 31 | 0.250 |
Why?
|
| Brain Edema | 4 | 2014 | 16 | 0.240 |
Why?
|
| Surgery, Computer-Assisted | 4 | 2017 | 57 | 0.240 |
Why?
|
| Child | 8 | 2020 | 2478 | 0.240 |
Why?
|
| Thalamus | 2 | 2015 | 33 | 0.220 |
Why?
|
| Glutamate Decarboxylase | 2 | 2017 | 17 | 0.220 |
Why?
|
| Postural Balance | 1 | 2016 | 180 | 0.210 |
Why?
|
| Benzenesulfonates | 1 | 2003 | 3 | 0.210 |
Why?
|
| Iodine Radioisotopes | 1 | 2003 | 16 | 0.200 |
Why?
|
| Pesticides | 1 | 2016 | 196 | 0.200 |
Why?
|
| Brachytherapy | 1 | 2003 | 24 | 0.200 |
Why?
|
| Occupational Exposure | 1 | 2016 | 231 | 0.200 |
Why?
|
| Catheterization | 1 | 2003 | 57 | 0.200 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 240 | 0.190 |
Why?
|
| Adenocarcinoma | 2 | 2017 | 300 | 0.190 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2014 | 29 | 0.190 |
Why?
|
| Neurons | 3 | 2015 | 416 | 0.190 |
Why?
|
| Transients and Migrants | 1 | 2016 | 298 | 0.190 |
Why?
|
| Brain Injuries | 2 | 2014 | 91 | 0.190 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2012 | 30 | 0.190 |
Why?
|
| Breast Neoplasms | 4 | 2017 | 754 | 0.180 |
Why?
|
| Cerebral Angiography | 2 | 2012 | 60 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2013 | 157 | 0.180 |
Why?
|
| Astrocytoma | 3 | 2018 | 29 | 0.180 |
Why?
|
| Receptor, EphA2 | 1 | 2021 | 13 | 0.170 |
Why?
|
| Radiation Dosage | 5 | 2020 | 84 | 0.170 |
Why?
|
| Sulfones | 1 | 2020 | 20 | 0.170 |
Why?
|
| Genomics | 2 | 2018 | 88 | 0.160 |
Why?
|
| Indans | 1 | 2020 | 34 | 0.160 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 44 | 0.160 |
Why?
|
| Registries | 2 | 2020 | 315 | 0.160 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 220 | 0.160 |
Why?
|
| Arnold-Chiari Malformation | 2 | 2010 | 8 | 0.160 |
Why?
|
| Hispanic Americans | 1 | 2016 | 930 | 0.160 |
Why?
|
| Brain Diseases | 1 | 2020 | 38 | 0.160 |
Why?
|
| Craniotomy | 3 | 2017 | 46 | 0.160 |
Why?
|
| Carcinoma | 1 | 2020 | 92 | 0.160 |
Why?
|
| Visual Perception | 1 | 2020 | 116 | 0.150 |
Why?
|
| Hydrocortisone | 4 | 2008 | 57 | 0.150 |
Why?
|
| Trigeminal Nerve | 2 | 2010 | 5 | 0.150 |
Why?
|
| Pain Measurement | 4 | 2014 | 356 | 0.150 |
Why?
|
| Reward | 2 | 2018 | 65 | 0.150 |
Why?
|
| Movement Disorders | 2 | 2010 | 26 | 0.150 |
Why?
|
| Prospective Studies | 7 | 2019 | 2327 | 0.150 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 102 | 0.140 |
Why?
|
| Multivariate Analysis | 6 | 2018 | 682 | 0.140 |
Why?
|
| Feedback, Psychological | 1 | 2018 | 6 | 0.140 |
Why?
|
| Cohort Studies | 5 | 2019 | 1844 | 0.140 |
Why?
|
| Pituitary Gland | 2 | 2008 | 9 | 0.140 |
Why?
|
| Disease Management | 2 | 2017 | 128 | 0.140 |
Why?
|
| Glomus Jugulare Tumor | 1 | 2017 | 4 | 0.130 |
Why?
|
| Basal Ganglia | 2 | 2014 | 16 | 0.130 |
Why?
|
| Neoplastic Stem Cells | 1 | 2018 | 98 | 0.130 |
Why?
|
| Time Factors | 7 | 2017 | 2183 | 0.130 |
Why?
|
| Weight Gain | 2 | 2015 | 112 | 0.130 |
Why?
|
| Medicare | 1 | 2018 | 213 | 0.130 |
Why?
|
| Brain Death | 2 | 2017 | 27 | 0.130 |
Why?
|
| Nervous System Neoplasms | 1 | 2017 | 8 | 0.130 |
Why?
|
| Signal Transduction | 1 | 2020 | 686 | 0.130 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 32 | 0.130 |
Why?
|
| Catheters, Indwelling | 2 | 2009 | 44 | 0.130 |
Why?
|
| Animals | 11 | 2021 | 7569 | 0.120 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 134 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2016 | 94 | 0.120 |
Why?
|
| Spinal Cord Injuries | 1 | 2016 | 40 | 0.120 |
Why?
|
| Risk Factors | 7 | 2019 | 3974 | 0.120 |
Why?
|
| Tremor | 1 | 2015 | 12 | 0.120 |
Why?
|
| Gene Transfer Techniques | 2 | 2017 | 65 | 0.120 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2018 | 192 | 0.120 |
Why?
|
| Retreatment | 3 | 2016 | 40 | 0.120 |
Why?
|
| Drug Implants | 1 | 2015 | 11 | 0.120 |
Why?
|
| Ganglioglioma | 1 | 2015 | 6 | 0.110 |
Why?
|
| Hypesthesia | 2 | 2015 | 9 | 0.110 |
Why?
|
| Central Nervous System Diseases | 1 | 2015 | 13 | 0.110 |
Why?
|
| Neurofibromatosis 2 | 1 | 2015 | 5 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2003 | 104 | 0.110 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2017 | 116 | 0.110 |
Why?
|
| Proportional Hazards Models | 5 | 2015 | 764 | 0.110 |
Why?
|
| Choice Behavior | 1 | 2015 | 86 | 0.110 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2014 | 35 | 0.110 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2014 | 7 | 0.110 |
Why?
|
| Incidence | 4 | 2020 | 1238 | 0.110 |
Why?
|
| Brain Stem Neoplasms | 1 | 2014 | 4 | 0.110 |
Why?
|
| Sheep | 4 | 2008 | 233 | 0.110 |
Why?
|
| Kidney Neoplasms | 2 | 2017 | 205 | 0.110 |
Why?
|
| Exotoxins | 2 | 2003 | 13 | 0.100 |
Why?
|
| Epidermal Growth Factor | 2 | 2003 | 21 | 0.100 |
Why?
|
| Diphtheria Toxin | 2 | 2003 | 26 | 0.100 |
Why?
|
| Interleukin-13 | 2 | 2003 | 28 | 0.100 |
Why?
|
| Carcinoma, Small Cell | 1 | 2013 | 22 | 0.100 |
Why?
|
| Vein of Galen Malformations | 1 | 2013 | 4 | 0.100 |
Why?
|
| Cerebral Veins | 1 | 2013 | 11 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2014 | 947 | 0.100 |
Why?
|
| Cerebral Cortex | 1 | 2014 | 126 | 0.100 |
Why?
|
| Tumor Burden | 4 | 2014 | 60 | 0.100 |
Why?
|
| Smoking | 1 | 2017 | 531 | 0.100 |
Why?
|
| Influenza Vaccines | 1 | 2014 | 83 | 0.100 |
Why?
|
| Skull Base Neoplasms | 1 | 2012 | 4 | 0.100 |
Why?
|
| Dose-Response Relationship, Radiation | 4 | 2015 | 82 | 0.100 |
Why?
|
| Spin Labels | 1 | 2012 | 25 | 0.100 |
Why?
|
| Fatal Outcome | 1 | 2012 | 82 | 0.100 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2012 | 3 | 0.100 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2012 | 13 | 0.100 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2012 | 26 | 0.100 |
Why?
|
| Scalp | 1 | 2012 | 36 | 0.090 |
Why?
|
| Skull | 1 | 2012 | 48 | 0.090 |
Why?
|
| Neurilemmoma | 1 | 2012 | 16 | 0.090 |
Why?
|
| Neoplasm Staging | 3 | 2015 | 470 | 0.090 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2012 | 4 | 0.090 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2012 | 18 | 0.090 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2012 | 22 | 0.090 |
Why?
|
| Arginine Vasopressin | 2 | 2008 | 3 | 0.090 |
Why?
|
| Procarbazine | 1 | 2011 | 5 | 0.090 |
Why?
|
| Resuscitation | 1 | 2012 | 67 | 0.090 |
Why?
|
| Hyperthermia, Induced | 1 | 2014 | 241 | 0.090 |
Why?
|
| Collagen Diseases | 1 | 2011 | 5 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 38 | 0.090 |
Why?
|
| Thalidomide | 1 | 2011 | 30 | 0.090 |
Why?
|
| Disease Progression | 3 | 2018 | 594 | 0.090 |
Why?
|
| Double-Blind Method | 3 | 2020 | 525 | 0.090 |
Why?
|
| Viruses | 1 | 2010 | 4 | 0.090 |
Why?
|
| Algorithms | 1 | 2014 | 511 | 0.080 |
Why?
|
| Medulloblastoma | 1 | 2010 | 7 | 0.080 |
Why?
|
| Vascular Diseases | 1 | 2011 | 68 | 0.080 |
Why?
|
| Blood-Brain Barrier | 1 | 2010 | 50 | 0.080 |
Why?
|
| Radiation Oncology | 1 | 2010 | 12 | 0.080 |
Why?
|
| Posture | 1 | 2010 | 56 | 0.080 |
Why?
|
| Lymphoma | 1 | 2010 | 33 | 0.080 |
Why?
|
| Age Factors | 1 | 2013 | 1197 | 0.080 |
Why?
|
| Deglutition Disorders | 1 | 2010 | 52 | 0.080 |
Why?
|
| Fetus | 3 | 2008 | 86 | 0.080 |
Why?
|
| Cognition Disorders | 1 | 2013 | 370 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2016 | 876 | 0.080 |
Why?
|
| Cell Line, Tumor | 3 | 2020 | 726 | 0.080 |
Why?
|
| Cell Proliferation | 3 | 2020 | 602 | 0.080 |
Why?
|
| North Carolina | 3 | 2016 | 1546 | 0.080 |
Why?
|
| Neurofibromatoses | 1 | 2008 | 2 | 0.070 |
Why?
|
| Mice, Nude | 2 | 2020 | 290 | 0.070 |
Why?
|
| Recurrence | 3 | 2015 | 282 | 0.070 |
Why?
|
| Ablation Techniques | 2 | 2018 | 24 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 532 | 0.070 |
Why?
|
| Databases, Factual | 2 | 2020 | 369 | 0.070 |
Why?
|
| Guanine | 1 | 2007 | 15 | 0.070 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 1 | 2006 | 7 | 0.060 |
Why?
|
| Cobalt Radioisotopes | 1 | 2006 | 3 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2020 | 1282 | 0.060 |
Why?
|
| Pregnancy, Animal | 1 | 2006 | 19 | 0.060 |
Why?
|
| Weight Loss | 1 | 2010 | 457 | 0.060 |
Why?
|
| Gestational Age | 4 | 2008 | 129 | 0.060 |
Why?
|
| Karnofsky Performance Status | 2 | 2018 | 11 | 0.060 |
Why?
|
| Receptors, Corticotropin | 1 | 2005 | 2 | 0.060 |
Why?
|
| Adrenal Glands | 1 | 2005 | 4 | 0.060 |
Why?
|
| Swine | 2 | 2016 | 216 | 0.060 |
Why?
|
| Supratentorial Neoplasms | 1 | 2004 | 3 | 0.060 |
Why?
|
| Fetal Development | 1 | 2004 | 27 | 0.060 |
Why?
|
| Adenoviridae | 1 | 2004 | 68 | 0.050 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2003 | 4 | 0.050 |
Why?
|
| DNA Methylation | 2 | 2015 | 144 | 0.050 |
Why?
|
| Cause of Death | 2 | 2015 | 240 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 456 | 0.050 |
Why?
|
| Mice | 2 | 2020 | 2511 | 0.050 |
Why?
|
| Renin-Angiotensin System | 1 | 2004 | 178 | 0.050 |
Why?
|
| Pituitary Gland, Anterior | 1 | 2003 | 2 | 0.050 |
Why?
|
| Hypothalamus | 1 | 2003 | 18 | 0.050 |
Why?
|
| Sheep, Domestic | 1 | 2003 | 18 | 0.050 |
Why?
|
| Adrenocorticotropic Hormone | 3 | 2008 | 19 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2017 | 459 | 0.050 |
Why?
|
| Equipment Design | 1 | 2003 | 179 | 0.050 |
Why?
|
| Pregnancy | 4 | 2008 | 981 | 0.050 |
Why?
|
| Intracranial Hemorrhages | 2 | 2013 | 33 | 0.050 |
Why?
|
| Quality of Life | 3 | 2018 | 961 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2003 | 308 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2016 | 754 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2016 | 1012 | 0.040 |
Why?
|
| Cytotoxins | 1 | 2021 | 13 | 0.040 |
Why?
|
| Dogs | 1 | 2021 | 120 | 0.040 |
Why?
|
| Dyskinesias | 1 | 2020 | 3 | 0.040 |
Why?
|
| Prevalence | 2 | 2014 | 1002 | 0.040 |
Why?
|
| Rats | 2 | 2016 | 1606 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 115 | 0.040 |
Why?
|
| Photic Stimulation | 1 | 2020 | 159 | 0.040 |
Why?
|
| Cell Movement | 1 | 2020 | 171 | 0.040 |
Why?
|
| Receptors, Interleukin | 3 | 2003 | 16 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 315 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 887 | 0.040 |
Why?
|
| United States | 2 | 2018 | 4108 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2018 | 99 | 0.040 |
Why?
|
| Necrosis | 1 | 2018 | 51 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2018 | 41 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2018 | 72 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 779 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2018 | 122 | 0.030 |
Why?
|
| Avoidance Learning | 1 | 2018 | 19 | 0.030 |
Why?
|
| Neuronavigation | 1 | 2017 | 8 | 0.030 |
Why?
|
| Parvovirinae | 1 | 2017 | 2 | 0.030 |
Why?
|
| Hearing Tests | 1 | 2017 | 13 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 881 | 0.030 |
Why?
|
| Hospitalization | 1 | 2020 | 488 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2017 | 148 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 264 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 245 | 0.030 |
Why?
|
| Blood Gas Analysis | 2 | 2008 | 17 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2016 | 31 | 0.030 |
Why?
|
| Games, Experimental | 1 | 2015 | 4 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 167 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2008 | 820 | 0.030 |
Why?
|
| DNA Modification Methylases | 1 | 2015 | 11 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2015 | 14 | 0.030 |
Why?
|
| Electrodes, Implanted | 1 | 2015 | 43 | 0.030 |
Why?
|
| Spinal Cord | 1 | 2016 | 121 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2016 | 203 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 70 | 0.030 |
Why?
|
| Action Potentials | 1 | 2015 | 186 | 0.030 |
Why?
|
| Levodopa | 1 | 2014 | 15 | 0.030 |
Why?
|
| Reoperation | 1 | 2015 | 260 | 0.030 |
Why?
|
| Influenza B virus | 1 | 2014 | 20 | 0.030 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2014 | 24 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2014 | 29 | 0.030 |
Why?
|
| Brain Stem | 1 | 2014 | 20 | 0.030 |
Why?
|
| Models, Animal | 1 | 2014 | 171 | 0.030 |
Why?
|
| Fetal Blood | 2 | 2005 | 38 | 0.030 |
Why?
|
| Receptors, Interleukin-13 | 2 | 2003 | 9 | 0.030 |
Why?
|
| Interleukin-13 Receptor alpha1 Subunit | 2 | 2003 | 10 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2014 | 107 | 0.030 |
Why?
|
| Models, Neurological | 1 | 2014 | 119 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 2003 | 160 | 0.030 |
Why?
|
| Pain | 1 | 2015 | 294 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 112 | 0.020 |
Why?
|
| Beta Rhythm | 1 | 2012 | 1 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 194 | 0.020 |
Why?
|
| Hypokinesia | 1 | 2012 | 3 | 0.020 |
Why?
|
| Antiparkinson Agents | 1 | 2012 | 10 | 0.020 |
Why?
|
| Embolization, Therapeutic | 1 | 2013 | 82 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2012 | 51 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2005 | 498 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 288 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2012 | 106 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2014 | 565 | 0.020 |
Why?
|
| Receptor, erbB-2 | 1 | 2012 | 65 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2012 | 106 | 0.020 |
Why?
|
| Radiography | 1 | 2013 | 386 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2012 | 38 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2012 | 99 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 114 | 0.020 |
Why?
|
| Radiometry | 1 | 2012 | 40 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 767 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 2014 | 193 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 363 | 0.020 |
Why?
|
| Facial Paralysis | 1 | 2011 | 7 | 0.020 |
Why?
|
| Hydrocephalus | 1 | 2011 | 12 | 0.020 |
Why?
|
| Survivors | 1 | 2013 | 168 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2011 | 40 | 0.020 |
Why?
|
| Otitis Media | 1 | 2011 | 23 | 0.020 |
Why?
|
| Pons | 1 | 2010 | 6 | 0.020 |
Why?
|
| Craniopharyngioma | 1 | 2010 | 8 | 0.020 |
Why?
|
| Spinal Nerve Roots | 1 | 2010 | 13 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2010 | 41 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 35 | 0.020 |
Why?
|
| Pituitary Neoplasms | 1 | 2010 | 17 | 0.020 |
Why?
|
| Medical Records | 1 | 2010 | 77 | 0.020 |
Why?
|
| Emaciation | 1 | 2010 | 4 | 0.020 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2011 | 148 | 0.020 |
Why?
|
| Gastroesophageal Reflux | 1 | 2010 | 20 | 0.020 |
Why?
|
| Essential Tremor | 1 | 2010 | 12 | 0.020 |
Why?
|
| Endoscopy | 1 | 2010 | 56 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 292 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2009 | 84 | 0.020 |
Why?
|
| Decompression, Surgical | 1 | 2009 | 56 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2008 | 69 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2008 | 79 | 0.020 |
Why?
|
| Asthma | 1 | 2010 | 262 | 0.020 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2007 | 1 | 0.020 |
Why?
|
| Body Weight | 1 | 2008 | 301 | 0.020 |
Why?
|
| Radioactivity | 1 | 2006 | 2 | 0.020 |
Why?
|
| Half-Life | 1 | 2006 | 22 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2007 | 97 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2008 | 125 | 0.020 |
Why?
|
| Adrenal Cortex | 1 | 2005 | 3 | 0.010 |
Why?
|
| Logistic Models | 1 | 2007 | 783 | 0.010 |
Why?
|
| Triiodothyronine | 1 | 2004 | 7 | 0.010 |
Why?
|
| Thyroxine | 1 | 2004 | 16 | 0.010 |
Why?
|
| Denervation | 1 | 2004 | 12 | 0.010 |
Why?
|
| Injections, Intralesional | 1 | 2004 | 14 | 0.010 |
Why?
|
| Viral Vaccines | 1 | 2004 | 12 | 0.010 |
Why?
|
| Adenovirus E1B Proteins | 1 | 2004 | 19 | 0.010 |
Why?
|
| Receptors, Angiotensin | 1 | 2004 | 61 | 0.010 |
Why?
|
| Virus Replication | 1 | 2004 | 42 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2004 | 67 | 0.010 |
Why?
|
| Renin | 1 | 2004 | 109 | 0.010 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2003 | 23 | 0.010 |
Why?
|
| Pseudomonas | 1 | 2003 | 6 | 0.010 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2003 | 6 | 0.010 |
Why?
|
| Receptors, Transferrin | 1 | 2003 | 10 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2003 | 71 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2003 | 64 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2003 | 55 | 0.010 |
Why?
|
| Survival | 1 | 2003 | 12 | 0.010 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 1 | 2003 | 1 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2003 | 60 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2003 | 186 | 0.010 |
Why?
|
| Receptors, Vasopressin | 1 | 2003 | 7 | 0.010 |
Why?
|
| Absorbable Implants | 1 | 2003 | 25 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 622 | 0.010 |
Why?
|
| Polymers | 1 | 2003 | 66 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2003 | 107 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 289 | 0.010 |
Why?
|
| Seizures | 1 | 2003 | 64 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2004 | 307 | 0.010 |
Why?
|
| Biocompatible Materials | 1 | 2003 | 233 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2003 | 475 | 0.010 |
Why?
|